Jul 26 |
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
|
Jul 24 |
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
|
Jul 24 |
Nuwellis to sell ~0.47M shares at $4.24 in registered direct offering
|
Jul 24 |
Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules
|
Jul 23 |
Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
|
Jul 17 |
Nuwellis reports first commercial sale of Quelimmune therapy to Cincinnati Children’s
|
Jul 17 |
Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s
|
Jul 12 |
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner
|
Jul 9 |
New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference
|
Jul 9 |
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
|